Muscular Dystrophy Clinical Trial
Official title:
A Two-part Multicenter Study: a Randomized, Double-blind, Placebo-controlled Dose-escalation Safety Phase (Part 1) Followed by Double-blind, Placebo-controlled, Adaptive Phase (Part 2) Study to Evaluate the Safety and Efficacy of AB-1003 in Adult Subjects With LGMD2I/R9 Mutations in the Gene Encoding Fukutin Related Protein (FKRP)
The purpose of this study is to evaluate the safety and tolerability of a single intravenous infusion of AB-1003 in adults diagnosed with limb girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Participants will be treated in sequential, dose-level cohorts. (Part 1)
Status | Recruiting |
Enrollment | 10 |
Est. completion date | December 2028 |
Est. primary completion date | December 2028 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Male and female subjects aged 18 and 65 years with clinical diagnosis of LGMD2I/R9 and confirmation of FKRP gene mutation. 2. Ability to ascend 4 stairs between 2.5 and 10 seconds. 3. Ability to walk/run 10 meters in < 30 seconds. 4. Able to understand and comply with all study procedures. 5. Sexually active females of childbearing potential and female and male partners of male subjects receiving AB-1003 must use a barrier method of contraception for the first 6 months after dosing. Exclusion Criteria: 1. Significant cardiomyopathy as defined by echocardiogram (left ventricular ejection fraction <40%), evidence of conduction defect (increased PR and RR intervals, left bundle branch block and QTcF >480m/sec), NYHA Class 3 or 4 heart failure, or MRI gadolinium enhancement evidence of clinically important myocardial fibrosis. 2. Contraindication to MRI or hypersensitivity to contrast dyes, shellfish or iodine. 3. Implanted spinal rods, cardiac pacemaker or other implantation that would distort cardiac MRI images. 4. History of chronic liver disease (e.g. hepatitis, HIV, steatosis) or abnormal liver function (abnormal GGT and/or abnormal total/direct bilirubin and/or AST and ALT >2 ULN). 5. Abnormal renal function (GFR < 60 ml/min, using the MDRD equation). 6. Any life-threatening disease, including malignant neoplasms and medical history or malignant neoplasms within the past 5 years prior to screening (except basal and squamous cell skin cancer). 7. In the opinion of the investigator, a pre-existing medical condition that predisposes the subject to risks that outweighs the potential benefits. 8. Requirement for daytime ventilatory support. 9. Change in glucocorticosteroid treatment within 3 months prior to baseline visit. 10. Exposure to another investigational drug within 3 months prior to study treatment or any previous treatment with gene therapy. 11. Ongoing participation in any other therapeutic clinical trial. 12. Neutralizing antibody titer to AAV9 = 1:5. 13. Female subjects who are pregnant, plan to become pregnant in the next 12 months, or breastfeeding. |
Country | Name | City | State |
---|---|---|---|
United States | Kennedy Krieger Institute | Baltimore | Maryland |
United States | University of Iowa | Iowa City | Iowa |
United States | University of California - Irvine | Irvine | California |
United States | University of Kansas Medical Center | Kansas City | Kansas |
United States | VCU | Richmond | Virginia |
United States | University of Washington Medical Center | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Asklepios Biopharmaceutical, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adverse Events | Treatment Emergent Adverse Events, Serious Adverse Events, Dose Limiting Toxicity | 0-52 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01834066 -
Study Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Muscular Dystrophy.
|
Phase 1/Phase 2 | |
Recruiting |
NCT01834040 -
Study Safety and Efficacy of BMMNC for the Patient With Duchenne Muscular Dystrophy
|
Phase 1/Phase 2 | |
Recruiting |
NCT00082108 -
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
|
||
Recruiting |
NCT00138931 -
Genetics of Cardiovascular and Neuromuscular Disease
|
||
Completed |
NCT00622453 -
Arrhythmias in Myotonic Muscular Dystrophy
|
N/A | |
Active, not recruiting |
NCT04038138 -
Clinical Trial Readiness Network FSHD France: Prospective 24 Months MRI Study
|
N/A | |
Completed |
NCT01451281 -
Studying Skeletal Muscle, Heart, and Diaphragm Imaging in Boys With Duchenne Muscular Dystrophy
|
||
Not yet recruiting |
NCT05470478 -
iBCI Optimization for Veterans With Paralysis
|
N/A | |
Completed |
NCT04154098 -
Evaluation of a Textile Scapula Orthosis
|
N/A | |
Terminated |
NCT02653833 -
The Study of Skeletal Muscle Blood Flow in Becker Muscular Dystrophy
|
Early Phase 1 | |
Not yet recruiting |
NCT06363526 -
Effectiveness of 5-week Digital Respiratory Practice in a Group of Children With Duchenne Muscular Dystrophy and Becker Muscular Dystrophy.
|
N/A | |
Completed |
NCT01990976 -
Study of Morphology and Functional Magnetic Resonance Imaging (MRI) Muscle Patients With Muscular Dystrophy Type FSHD Benefiting a Physical Training Introduced.
|
N/A | |
Completed |
NCT01393444 -
ECoG Direct Brain Interface for Individuals With Upper Limb Paralysis
|
N/A | |
Recruiting |
NCT00912041 -
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
|
N/A | |
Completed |
NCT00866112 -
A Randomized Exercise Trial for Wheelchair Users
|
N/A | |
Completed |
NCT01882400 -
Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy
|
Phase 4 | |
Recruiting |
NCT05726591 -
Evaluating Long-term Use of a Pediatric Robotic Exoskeleton (P.REX/Agilik) to Improve Gait in Children With Movement Disorders
|
N/A | |
Completed |
NCT02815878 -
Enhance Wellness for Individuals With Long-Term Physical Disabilities
|
N/A | |
Completed |
NCT04035967 -
Investigation of Parents' Anxiety Level and Health Related Quality of Life in Different Types of Physical Disabilities
|
||
Not yet recruiting |
NCT06290713 -
Vasodilator and Exercise Study for DMD (VASO-REx)
|
Phase 2 |